KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average (2016 - 2026)

Supernus Pharmaceuticals has reported Equity Average over the past 14 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Equity Average rose 3.35% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 3.35% year-over-year, with the annual reading at $1.0 billion for FY2025, 7.16% up from the prior year.
  • Equity Average was $1.1 billion for Q4 2025 at Supernus Pharmaceuticals, roughly flat from $1.1 billion in the prior quarter.
  • Over five years, Equity Average peaked at $1.1 billion in Q3 2025 and troughed at $749.7 million in Q1 2021.
  • The 5-year median for Equity Average is $916.0 million (2023), against an average of $910.9 million.
  • Year-over-year, Equity Average rose 24.03% in 2021 and then rose 2.91% in 2024.
  • A 5-year view of Equity Average shows it stood at $813.2 million in 2021, then rose by 6.93% to $869.5 million in 2022, then grew by 5.45% to $916.9 million in 2023, then rose by 11.41% to $1.0 billion in 2024, then grew by 3.35% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Equity Average are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025).